Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David B. Page, Ahmed Elkhanany, Laila Samiian, Jailan Elayoubi, Rakhshanda Layeequr Rahman, Eduardo Dias, Alfredo A. Santillan, Eric Allen Brown, Linsey P. Gold, Laurie Beth Matt-Amaral, Nayana Dekhne, Beth-Ann Lesnikoski, Regina Hampton, Henry Jacob Conter, Sahra Uygun, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy
Institutions: Providence Portland Medical Center, Baylor College of Medicine, Baptist MD Anderson Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Texas Tech University, Texas Tech University Health Sciences Center, Cleveland Clinic Akron General, Beaumont Hospital, Royal Oak, William Osler Health System, Agendia (United States), Baylor University Medical Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7162494782
Cites:
Cited by:
Related to: